Oral S-1 + Oral Osimertinib
Phase 2Small molecule
Oral S-1 + Oral Osimertinib is one of 9 small molecule programs targeting NSCLC. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in NSCLC
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Phase 3
Alunbrig
TakedaPhase 2
Poziotinib
Spectrum Pharmaceuticals, IncPhase 3
Tyrosine Kinase Inhibitor
PfizerPhase 2
SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
Alimta
GGynecologic Oncology Group
Preclinical
Oral S-1 + Oral Osimertinib
NNational Cancer Centre, Singapore
Phase 2
Platinum Chemotherapy
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oral S-1 + Oral Osimertinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details